ACEA Biosciences to be Acquired by Agilent Technologies
September 26 2018 - 6:00AM
Business Wire
Cell Analysis Just Got Better!
ACEA Biosciences announced today that it has signed a definitive
agreement to join Agilent Technologies, Inc. (NYSE: A).
ACEA Biosciences is a company known for developing highly
innovative products, which are used in academia, as well as the
biotech and pharmaceutical industries. In recent years, the ACEA
xCELLigence® RTCA technology has blazed a trail in immuno-oncology,
pre-clinical drug discovery and development, as well as in basic
academic research. The technology is complemented by the
introduction in recent years of the NovoCyte® and NovoCyte
Quanteon™ portfolio of high performance benchtop flow cytometry
systems.
Both ACEA and Agilent have a great reputation for scientific and
technical innovation, and for building systems and products of
exceptional quality. As part of Agilent, ACEA will be able to
leverage an unmatched global infrastructure of service and support,
as well as a powerful global marketing and sales engine.
Complementary engineering and scientific expertise from both
companies should also provide a rich pipeline of novel systems and
products well into the future.
“The analytical instruments, systems, and software developed by
ACEA dovetail perfectly with the strategic vision and mission of
Agilent Technologies,” stated Xiao Xu, Chief Executive Officer of
ACEA. “Agilent also has a number of complementary technologies,
used in immuno-oncology and drug discovery, which should provide
tremendous synergies.”
“ACEA represents a unique opportunity for Agilent to expand its
team and broaden its portfolio with highly complementary
technology, increasing the relevance and impact we can have with
our customers in the cell analysis space,” said Todd Christian,
Vice President & General Manager of Agilent’s Cell Analysis
Division. “We share the same passion around the need for and
innovation of live-cell, kinetic, and label free approaches to cell
analysis extending beyond traditional end-point measurements.
Together, we will be able to offer a more comprehensive and
compelling product portfolio to our collective customers.”
“Agilent and ACEA are aligned with a common mission to provide
innovative high-performance solutions that help our customers
advance scientific discovery and improve healthcare,” said Xiaobo
Wang, President and Chief Technology Officer (CTO) of ACEA. “We are
excited for the opportunities that this unique combination will
create for both our employees and our customers.”
Agilent Technologies Inc. (NYSE: A) is headquartered in Santa
Clara, and is a global leader in life sciences, diagnostics, and
applied chemical markets.
About xCELLigence® Real Time Cell Analysis (RTCA)
Instruments
The xCELLigence® RTCA instruments use noninvasive biosensors to
monitor and quantify cell proliferation, cell health, morphology
changes, and attachment quality in a label-free, real-time manner.
The xCELLigence RTCA instruments are being used in the academia,
pharmaceutical, and biotech industries for applications ranging
from cancer immunotherapy, cardiotoxicity, and drug discovery. To
date, xCELLigence has been used in more than 1,400 publications,
which can be viewed in a searchable library.
About NovoCyte® Flow Cytometers
The NovoCyte® and Novocyte Quanteon™ are high performance
benchtop flow cytometers that are accessible to all levels of
users. With one to three different laser options and a highly
customizable optical platform, the NovoCyte® can be configured for
diverse applications and is readily upgradeable over time. The
NovoCyte Quanteon™ flow cytometer builds upon its wildly successful
predecessor, the NovoCyte™, and provides an expanded set of
capabilities that easily accommodate the large, multi-color panels
found in today’s highly progressive flow cytometry laboratories.
Scientists now have the flexibility to choose from 25 fluorescent
channels utilizing four lasers (405, 488, 561, and 637nm) with 25
independent silicon photomultiplier (SiPM) detectors.
About ACEA Biosciences
Founded in 2002, ACEA Biosciences is a pioneer in the
development and commercialization of high performance, cutting edge
cell analysis platforms for life science research. ACEA’s
xCELLigence impedance-based, label-free, real-time cell analysis
instruments and NovoCyte® flow cytometers are used in pre-clinical
drug discovery and development, toxicology, safety pharmacology,
and basic academic research. More than 2,300 instruments have been
placed globally.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. With more than
50 years of insight and innovation, Agilent instruments, software,
services, solutions, and people provide trusted answers to its
customers' most challenging questions. The company generated
revenues of $4.47 billion in fiscal 2017 and employs 14,200 people
worldwide. Information about Agilent is available at
www.agilent.com.
For more information visit http://www.aceabio.comFollow on
Linked In, Twitter, and Facebook
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180926005271/en/
ACEA Biosciences, Inc.J. Michael Honeysett, MBAVice President of
Global Commercialization858-299-8040mhoneysett@aceabio.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Sep 2023 to Sep 2024